Stocks Overview

LAST PRICE
100.0000
TODAY'S CHANGE (%)
Trending Down-2.3600 (-2.3056%)

Bid / Lots
99.9100/ 2
Ask / Lots
100.0400/ 2
Open / Previous Close
100.8800 / 102.3600
Day Range
Low 99.1600
High 101.5400
52 Week Range
Low 43.8900
High 111.0200
Volume
184,324
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Tuesday's close: 102.36
Time	Volume	BPMC
09:32 ET	5060	100.1083
09:34 ET	100	100.84
09:38 ET	116	100.91
09:41 ET	100	101
09:43 ET	100	100.84
09:54 ET	200	100.49
09:56 ET	300	100.51
09:59 ET	400	100.87
10:01 ET	414	100.65
10:03 ET	100	100.65
10:06 ET	100	100.7
10:10 ET	100	100.79
10:15 ET	100	101.19
10:17 ET	153	101.405
10:19 ET	300	101.405
10:21 ET	400	101.395
10:24 ET	800	101.21
10:26 ET	4500	100.625
10:28 ET	949	100.38
10:30 ET	238	100.45
10:32 ET	200	100.86
10:33 ET	500	100.71
10:35 ET	200	100.77
10:39 ET	300	100.97
10:42 ET	600	100.945
10:44 ET	200	100.85
10:46 ET	200	100.705
10:48 ET	698	100.82
10:51 ET	200	100.86
10:53 ET	300	100.835
10:55 ET	300	100.61
10:57 ET	100	100.6525
11:00 ET	4506	100.35
11:04 ET	500	100.365
11:06 ET	100	100.31
11:08 ET	300	100.15
11:09 ET	736	99.86
11:11 ET	200	99.73
11:13 ET	400	99.7
11:15 ET	300	99.8
11:18 ET	500	99.94
11:20 ET	800	100
11:22 ET	200	100.115
11:24 ET	1300	100.02
11:26 ET	898	100
11:27 ET	700	100.36
11:29 ET	100	100.4075
11:33 ET	300	100.325
11:36 ET	200	100.27
11:40 ET	100	100.605
11:42 ET	200	100.55
11:44 ET	100	100.57
11:45 ET	100	100.335
11:47 ET	1300	100.395
11:49 ET	453	100.326
11:51 ET	1532	100.04
11:58 ET	603	100.32
12:07 ET	100	100.3025
12:09 ET	200	100.13
12:12 ET	700	100.26
12:16 ET	600	100.14
12:18 ET	400	100.135
12:23 ET	517	100.15
12:27 ET	900	100.01
12:32 ET	100	100.03
12:34 ET	422	100.045
12:36 ET	400	100
12:38 ET	200	99.99
12:39 ET	200	99.91
12:45 ET	200	99.97
12:48 ET	600	100.03
12:54 ET	778	99.855
12:56 ET	100	99.84
12:57 ET	100	99.865
12:59 ET	839	99.615
01:01 ET	8622	99.61
01:06 ET	100	99.64
01:08 ET	200	99.39
01:15 ET	100	99.23
01:17 ET	100	99.16
01:19 ET	100	99.26
01:21 ET	400	99.565
01:24 ET	100	99.565
01:26 ET	100	99.41
01:32 ET	2852	99.98
01:33 ET	3200	99.57
01:35 ET	200	99.51
01:37 ET	400	99.58
01:39 ET	100	99.69
01:44 ET	300	99.43
01:46 ET	700	99.325
01:48 ET	300	99.4
01:50 ET	800	99.55
01:53 ET	700	99.705
01:55 ET	1800	99.47
02:00 ET	200	99.435
02:02 ET	1100	99.51
02:06 ET	200	99.63
02:08 ET	100	99.67
02:09 ET	1100	99.89
02:11 ET	300	99.7675
02:13 ET	1200	100.07
02:18 ET	1300	99.93
02:20 ET	400	99.935
02:22 ET	944	100.005
02:24 ET	400	99.8
02:26 ET	2560	100.095
02:27 ET	200	100.11
02:29 ET	675	99.825
02:31 ET	1800	99.985
02:33 ET	525	99.855
02:36 ET	234	99.875
02:38 ET	200	99.81
02:40 ET	900	99.95
02:42 ET	240	99.98
02:44 ET	500	99.99
02:45 ET	1302	99.86
02:47 ET	4828	100.005
02:49 ET	300	99.98
02:51 ET	14437	100.295
02:54 ET	100	100.26
02:56 ET	400	100.12
02:58 ET	500	100.12
03:00 ET	800	100.135
03:02 ET	600	99.85
03:03 ET	100	99.97
03:05 ET	989	99.995
03:07 ET	549	100
03:09 ET	3872	100.095
03:12 ET	700	99.94
03:14 ET	300	100
03:16 ET	800	100
03:18 ET	200	100

Data delayed at least 15 minutes.

Today
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 2 hours ago by Dow Jones
  2 hours ago by Dow Jones
Yesterday
- INVESTIGATION ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 12:47PM ET on Tuesday May 28, 2024 by Dow Jones
  12:47PM ET on Tuesday May 28, 2024 by Dow Jones
May 27, 2024
- IMPORTANT STOCKHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 11:31PM ET on Monday May 27, 2024 by Dow Jones
  11:31PM ET on Monday May 27, 2024 by Dow Jones
May 26, 2024
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medicines Corporation and Encourages Investors to Contact the Firm, from 8:12PM ET on Sunday May 26, 2024 by Dow Jones
  8:12PM ET on Sunday May 26, 2024 by Dow Jones
May 23, 2024
- Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting, from 5:05PM ET on Thursday May 23, 2024 by Dow Jones
  5:05PM ET on Thursday May 23, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesBPMC Blueprint Medicines Corp	6.4B	-20.7x	---
United StatesINSM Insmed Inc	7.1B	-9.9x	---
United StatesLEGN Legend Biotech Corp	7.6B	-16.1x	---
United StatesRVMD Revolution Medicines Inc	6.3B	-10.0x	---
United StatesITCI Intra-Cellular Therapies Inc	6.9B	-57.9x	---
United StatesASND Ascendis Pharma A/S	7.4B	-13.7x	---
As of 2024-05-29

Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Contact Information

Headquarters: 45 Sidney StreetCAMBRIDGE, MA, United States 02139
Phone: 617-374-7580
Fax: 302-655-5049

Executives

Chairman of the Board: Jeffrey Albers
President, Chief Executive Officer, Director: Kathryn Haviland
Chief Financial Officer: Michael Landsittel
President - Research and Development: Fouad Namouni
Chief Operating Officer: Christina Rossi

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$6.4B
Revenue (TTM)	$282.2M
Shares Outstanding	62.6M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.69
EPS	$-4.82
Book Value	$2.14
P/E Ratio	-20.7x
Price/Sales (TTM)	22.7
Price/Cash Flow (TTM)	---
Operating Margin	-94.69%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Blueprint Medicines Corp
NASDAQ:BPMCUnited States

Search Criteria

Charts

Recent News

Today

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 2 hours ago by Dow Jones

Yesterday

INVESTIGATION ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 12:47PM ET on Tuesday May 28, 2024 by Dow Jones

May 27, 2024

IMPORTANT STOCKHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 11:31PM ET on Monday May 27, 2024 by Dow Jones

May 26, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medicines Corporation and Encourages Investors to Contact the Firm, from 8:12PM ET on Sunday May 26, 2024 by Dow Jones

May 23, 2024

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting, from 5:05PM ET on Thursday May 23, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar